Principal Investigator,Professor :

WANG Qihui
Address:NO.1 West Beichen Road, Chaoyang District, Beijing 100101, China
Research Interests
1.1.Emerging and re-emerging infectious disease, especially the invasion and cross-species transmission of coronaviruses.
2.2.Development of Antibody drug for viral infectious diseases.
3.3.mRNA vaccine design and evaluation.
B.S. 2006 Biological Engineering, Harbin Institute of Technology
Ph.D. 2012 Institute of Biophysics, Chinese Academy of Sciences (CAS)
Work experience
Post-doctoral fellow training
2012-2014 Dr. George F. Gao’ Lab, Institute of Microbiology, CAS, Beijing
2017-2017 Dr. Zhiqiang An’s Lab, Health Science Center, University of Texas, Houston, USA
Professional Appointments
2014-2015 Assistant Professor, IMCAS
2015-2019 Associate Professor, IMCAS
2019-present Principal Investigator, Professor and Ph.D. advisor, IMCAS
The main research areas
Viral infection mechanism, Antibody development, mRNA vaccine development.

1.Wang Q*, Chen H, Shi Y, Hughes AC, Liu JW, Jiang J, Gao FG, Xue Y, Tong Y. Tracing the origins of SARS-CoV-2: lessons learned from the past. Cell Research 2021. 31:1139-1141.

2.Niu S#, Wang J#, Bai B, Wu L, Chen Q, Du P, Han P, Zhang Y, Jia Y, Qiao C, Qi J, Tian W*, Wang H*, Wang Q*, Gao FG*. Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin. EMBO Journal (Cover story). 2021 40(16):e107786.

3.Liu K#, Pan X#, Li L#, Yu F#, Zheng A, Du P, Han P, Meng Y, Zhang Y, Wu L, Chen Q, Song C, Jia Y, Niu S, Lu D, Qiao C, Chen Z, Ma D, Ma X, Tan S, Zhao X, Qi J*, Gao FG*, Wang Q*. Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species, Cell 2021. 184:1-14.

4.Liu K#, Tan S#, Niu S#, Wang J#, Wu L, Sun H, Zhang Y, Pan x, Qu X, Meng Y, Jia Y, Chen Q, Deng C, Yan J, Wang H-W, Wang Q*, Qi J*, Gao GF*. Cross-species recognition of SARS-CoV-2 to bat ACE2. Proc Natl Acad Sci U S A 2021. Jan 5;118(1):e2020216118.

5.仵丽丽、苏佳岐、牛胜、陈茜、张艳芳、严景华、施一、齐建勋、高福*、王奇慧*,新型冠状病毒结合穿山甲ACE2受体的分子机制. 科学通报 2021.66 (1), 73-84.

6.Wu L#, Chen Q#, Liu K#, Wang J#, Han P, Zhang Y, Hu Y, Meng Y, Pan X, Qiao C, Tian S, Du P, Song H, Shi W, Qi J, Wang HW*, Yan J*, George, F. G,Wang Q*. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discovery 2020. 6:68.

7.Bai C#, Cai J#, Han P, Qi J, Yuen K-Y, Wang Q*. The crystal structure of the emerging human-infection hepatitis E virus E2s protein. Biochemical and Biophysical Research Communications 2020. 532(1):25-31.

8.Sun H#, Li Y#, Liu P#, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G*, Yan J, Gao FG, Qi J* and Wang Q*. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerging Microbes & Infections 2020. 9(1):1238-1241.

9.Shi R#, Shan C#, Duan X#, Chen Z#, Liu P#, Song J#, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS*, Wang Q*, Gao FG*, Yuan Z* and Yan J*. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 2020. 584(7819):120-124.

10.Wang Qand Yan J. Isolation of Monoclonal Antibodies from Zika Virus-Infected Patient Samples. Methods in molecular biology (Clifton, N.J.) 2020. 2142:261-288.

11.Wang, Q#, Zhang, Y#, Wu, L#, Niu, S#, Song, C#, Zhang, Z, Lu, G, Qiao, C, Hu, Y, Yuen, K-Y, Wang, QS, Zhou, H, Yan J* and Qi J*. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell2020. 181(4):894-904.e9.

12.Yuan Y, Qi J, Peng R, Li C, Lu G, Yan J, Wang Q*,Gao GF*. Molecular basis of binding between MERS-CoV and CD26s from seven bat species. Journal of Virology 2020. 94: e01387-19.

13.Wang Q*#, Song H#, Cheng H, Qi J, Nam G, Tan S, Wang J, Fang M, Shi Y, Tian Z, Cao X, An Z, Yan J, Gao GF*. 2019. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cellular & Molecular Immunology 2020. 17(9):966-975.

14.Wang Q#, Ma T#, Wu Y#, Chen Z#, Zeng H, Tong Z, Gao F, Qi J, Zhao Z, Chai Y, Yang H, Wong G, Bi Y, Wu L, Shi R, Yang M, Song J, Jiang H, An Z, Wang J, Yilma TD, Shi Y, Liu WJ, Liang M, Qin C, Gao GF*, Yan J*. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nature Microbiology 2019. 500: 227-31.

15.Wang Q*, Yan J, Gao GF. Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design. Journal of Virology 2017. 91:e01049-01017.

16.Wang Q#, Yang H#, Liu X#, Dai L#, Ma T, Qi J, Wong G, Peng R, Liu S, Li J, Li S, Song J, Liu J, He J, Yuan H, Xiong Y, Liao Y, Li J, Yang J, Tong Z, Griffin BD, Bi Y, Liang M, Xu X, Qin C, Cheng G, Zhang X, Wang P, Qiu X, Kobinger G, Shi Y, Yan J*, Gao GF*. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus.Science Translational Medicine2016. 8:369ra179.

17.Wang Q*, Wong G, Lu G, Yan J, Gao GF*. MERS-CoV spike protein: Targets for vaccines and therapeutics. Antiviral Research 2016. 133:165-177.

18.Wang Q#, Qi J, Yuan Y, Xuan Y, Han P, Wan Y, Ji W, Li Y, Wu Y, Wang J, Iwamoto A, Woo PC, Yuen KY, Yan J, Lu G, Gao GF. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host & Microbe 2014. 16:328-337.

19.Lu G#, Hu Y#, Wang Q#, Qi J#, Gao F#, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang B, Shi Y, Yan J, Gao GF. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013. 500:227-231.